Lasbleiz Adèle, Cariou Bertrand, Darmon Patrice, Soghomonian Astrid, Ancel Patricia, Boullu Sandrine, Houssays Marie, Romain Fanny, Lagier Jean Christophe, Boucekine Mohamed, Resseguier Noémie, Gourdy Pierre, Pichelin Matthieu, Wargny Matthieu, Dutour Anne, Gaborit Bénédicte
Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, 13005 Marseille, France.
Aix Marseille University, INSERM, INRAE, C2VN, 13005 Marseille, France.
J Clin Med. 2020 Nov 20;9(11):3726. doi: 10.3390/jcm9113726.
Diabetes mellitus (DM) has been identified as a risk factor for severe COVID-19. DM is highly prevalent in the general population. Defining strategies to reduce the health care system burden and the late arrival of some patients thus seems crucial. The study aim was to compare phenotypic characteristics between in and outpatients with diabetes and infected by COVID-19, and to build an easy-to-use hospitalization prediction risk score. This was a retrospective observational study. Patients with DM and laboratory- or CT-confirmed COVID-19, who did ( = 185) and did not ( = 159) require hospitalization between 10 March and 10 April 2020, were compared. Data on diabetes duration, treatments, glycemic control, complications, anthropometrics and peripheral oxygen saturation (SpO) were collected from medical records. Stepwise multivariate logistic regressions and ROC analyses were performed to build the DIAB score, a score using no more than five easy-to-collect clinical parameters predicting the risk of hospitalization. The DIAB score was then validated in two external cohorts ( = 132 and = 2036). Hospitalized patients were older (68.0 ± 12.6 vs. 55.2 ± 12.6 years, < 0.001), with more class III obesity (BMI ≥ 40 kg/m, 9.7 vs. 3.5%, = 0.03), hypertension (81.6 vs. 44.3%, < 0.0001), insulin therapy (37% vs. 23.7%, = 0.009), and lower SpO (91.6 vs. 97.3%, < 0.0001) than outpatients. Type 2 DM (T2D) was found in 94% of all patients, with 10 times more type 1 DM in the outpatient group (11.3 vs. 1.1%, < 0.0001). A DIAB score > 27 points predicted hospitalization (sensitivity 77.7%, specificity 89.2%, AUC = 0.895), and death within 28 days. Its performance was validated in the two external cohorts. Outpatients with diabetes were found to be younger, with fewer diabetic complications and less severe obesity than inpatients. DIAB score is an easy-to-use score integrating five variables to help clinicians better manage patients with DM and avert the saturation of emergency care units.
糖尿病(DM)已被确定为重症新型冠状病毒肺炎(COVID-19)的一个风险因素。DM在普通人群中高度流行。因此,制定策略以减轻医疗保健系统负担以及减少一些患者的延迟就诊似乎至关重要。本研究的目的是比较感染COVID-19的糖尿病住院患者和门诊患者的表型特征,并建立一个易于使用的住院预测风险评分。这是一项回顾性观察研究。比较了2020年3月10日至4月10日期间确诊感染COVID-19且需要住院治疗(n = 185)和不需要住院治疗(n = 159)的糖尿病患者。从病历中收集了糖尿病病程、治疗方法、血糖控制情况、并发症、人体测量学数据和外周血氧饱和度(SpO)。进行逐步多因素逻辑回归和ROC分析以建立DIAB评分,该评分使用不超过五个易于收集的临床参数来预测住院风险。然后在两个外部队列(n = 132和n = 2036)中对DIAB评分进行验证。住院患者年龄更大(68.0±12.6岁 vs. 55.2±12.6岁,P < 0.001),III级肥胖(BMI≥40 kg/m²)更多(9.7% vs. 3.5%,P = 0.03),高血压更多(81.6% vs. 44.3%,P < 0.0001),接受胰岛素治疗的比例更高(37% vs. 23.7%,P = 0.009),且SpO更低(91.6% vs. 97.3%,P < 0.0001)。所有患者中94%为2型糖尿病(T2D),门诊组1型糖尿病患者是住院组的10倍(11.3% vs. 1.1%,P < 0.0001)。DIAB评分>27分可预测住院(敏感性77.7%,特异性89.2%,AUC = 0.895)以及28天内死亡。其性能在两个外部队列中得到验证。发现糖尿病门诊患者比住院患者更年轻,糖尿病并发症更少,肥胖程度也较轻。DIAB评分是一个易于使用的评分,整合了五个变量,可帮助临床医生更好地管理糖尿病患者并避免急诊室饱和。